Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP-HepB
- Development stage
- Preclinical
- Lead developer
- Global Biotech Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP-HepB (also known as DTacP-HepB) is a combination vaccine candidate designed to immunize against four infectious diseases: diphtheria, tetanus, pertussis (whooping cough), and hepatitis B. It was initiated as a development project in 2012 by Global Biotech Products (GBP, formerly GPO-MBP), a joint venture between Thailand's Government Pharmaceutical Organization (GPO) and Sanofi Pasteur. The vaccine is formulated with diphtheria toxoid, tetanus toxoid, acellular pertussis antigens, and hepatitis B surface antigen (HBsAg) to stimulate the production of protective antibodies against *Corynebacterium diphtheriae*, *Clostridium tetani*, *Bordetella pertussis*, and Hepatitis B virus. It is designed to provide a safer profile with fewer side effects compared to whole-cell pertussis combination vaccines.
- Other names
- DTacP-HepBDTacP-HepB vaccineDTaP-HepB vaccinediphtheria, tetanus, acellular pertussis, and hepatitis B vaccine
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)HBsAg (Hepatitis B surface antigen)PRN (Pertactin)ETV6 (ETS variant transcription factor 6)
Beyond the preview
Go deeper on DTaP-HepB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP-HepB.